Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat
Myrthe J. van Dijk(Utrecht University), Eduard J. van Beers(Utrecht University), Marije Bartels(University Medical Center Utrecht), Marjon H. Cnossen(Erasmus MC), Erfan Nur(Sanquin), Minke A.E. Rab(Utrecht University), Cleo Derichs(Utrecht University), Anita W. Rijneveld(Erasmus MC Cancer Institute), Bart J. Biemond(Amsterdam University Medical Centers), Richard van Wijk(Utrecht University), Judith Jans(University Medical Center Utrecht), Brigitte A. van Oirschot(Utrecht University), Jennifer Bos(Utrecht University), Sigrid van der Veen(Utrecht University)
Cited by 2
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162